New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma
- Sunday, December 6, 2020, 7:14
- PR Newswire
- Add a comment
BEDMINSTER, N.J., Dec. 6, 2020 /PRNewswire/ — Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced data from two post-hoc analyses of the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In…
About the Author
admin has written 20652 stories on this site.